Precision Medicine News and Updates | Precision Medicine Online
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues. Amgen Sees Strong Growth for Precision Oncology Drugs in Q3. Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
Breaking News - Precision Medicine Online
3 days ago · Viracta Therapeutics Cutting 42 Percent of Workforce, Reducing Board Seats in Restructuring. The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market. Nov 07, 2024.
Precision Oncology News - Precision Medicine Online
Nov 8, 2024 · NCCN Adds Prostate Cancer to Genetic Risk Assessment Guidelines. Nov 7, 2024. Gilead Sciences Focuses on New Multiple Myeloma CAR T Amid Flat Q3 Cell Therapy Sales. Nov 6, 2024.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced …
10 hours ago · NEW YORK – The authors of a paper published this month want to establish reduced penetrance pathogenic variants (RPPVs) as a new category of BRCA1/2 variants associated with a lower risk of hereditary breast cancer than high-penetrance variants and that carriers of RPPVs should be managed differently.
Autoimmune Disease Research News - Precision Medicine Online
Jul 11, 2024 · Kyverna Therapeutics Gets FDA Permission to Study CAR T-Cell Therapy in Multiple Sclerosis. News on research and diagnostics in autoimmune disorders including rheumatoid arthritis, lupus, multiple sclerosis, and more from Precision Medicine Online.
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy …
12 hours ago · NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use on Friday recommended approval of Bristol Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) plus its CTLA-4 inhibitor Yervoy (ipilimumab) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer.
Genomics Technology, Tools & Methods - Precision Medicine Online
Oct 29, 2024 · Sep 11, 2024. New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary. Load More. The latest news on life science tools and technology in genetics, genomics, and molecular diagnostics from Precision Medicine Online.
Precision Oncology Precision Oncology News - Precision Medicine …
Oct 7, 2024 · The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Business & Financial News | Precision Medicine Online
Oct 28, 2024 · Ocuphire Pharma, Opus Genetics Merge in All-Stock Deal. Oct 23, 2024. Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth. Load More. Read breaking news on Precision Oncology business, policy & funding. Find updates in the life science and diagnostics business world from Precision Medicine Online.
Genomics Research & Discovery | Precision Medicine Online
Oct 7, 2024 · Starting next year, the network will implement a population genomic screening pilot program for common, actionable genomic conditions in a primary care setting over five years. Researchers will evaluate the clinical effectiveness and economic impact of this approach through a small study at a single ...